The anti-anginal drug trimetazidine reduces neutrophil-mediated cardiac reperfusion injury

Journal of Cardiovascular Pharmacology

Volumn 46, Issue 1, 2005, Pages 89-98

  Tritto, Isabella ^a,b   Wang, Penghai ^a   Kuppusamy, Periannan ^a   Giraldez, Roberto ^a   Zweier, Jay L ^a   Ambrosio, Giuseppe ^a,b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PERUGIA   (Italy)

Author keywords

Myocardial ischemia; Neutrophils; Oxygen radicals; Reperfusion injury; Trimetazidine

Indexed keywords

ANTIANGINA PECTORIS AGENT; HYDROXYL RADICAL; SUPEROXIDE; TRIMETAZIDINE;

ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; DRUG EFFECT; DRUG INFUSION; ELECTRON SPIN RESONANCE; FEMALE; HEART CONTRACTION; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HUMAN; HUMAN CELL; IN VITRO STUDY; LEUKOCYTE ACTIVATION; NONHUMAN; PRIORITY JOURNAL; RAT; REPERFUSION INJURY;

ANIMALS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HEART; HUMANS; LUMINESCENT MEASUREMENTS; MYOCARDIAL REPERFUSION INJURY; N-FORMYLMETHIONINE LEUCYL-PHENYLALANINE; NEUTROPHIL ACTIVATION; NEUTROPHILS; RATS; RATS, SPRAGUE-DAWLEY; REACTIVE OXYGEN SPECIES; TIME FACTORS; TRIMETAZIDINE; VASODILATOR AGENTS; XANTHINE OXIDASE;

EID: 21444448415     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.fjc.0000164091.81198.a3     Document Type: Article

References (54)

1. McClellan KJ, Plosker GL. Trimetazidine: a review of its use in stable angina pectoris and other coronary conditions. Drugs. 1999;58:143-157.
2. Marzilli M. Cardioprotective effects of trimetazidine: a review. Curr Med Res Opin. 2003;19:661-672.
3. Barsotti A, Di Napoli P. Trimetazidina e cardioprotezione durante ischemia-riperfusione. Ital Heart J. 2004;5:S29-S36.
4. Aussedat J, Ray A, Kay L, et al. Improvement of long term preservation of isolated arrested rat heart: beneficial effect of the antiischemic agent trimetazidine. J Cardiovasc Pharmacol. 1993;21:128-135.
5. Drake-Holland AJ, Belcher PR, Hynd J. Infarct size in rabbits: a modified method illustrated by the effects of propanolol and trimetazidine. Basic Res Cardiol. 1993;88:250-258.
6. Fantini E, Demaison L, Sentexe, et al. Some biochemical aspects of the protective effects of trimetazidine on rat cardiomyocytes during hypoxia and reoxygenation. J Mol Cell Cardiol. 1994;26:6949-6958.
7. Noble MI, Belcher PR, Drake-Holland AJ. Limitation of infarct size by trimetazidine in the rabbit. Am J Cardiol. 1995;76:41B-44B.
8. Schofield RS, Hill JA. Role of metabolically active drugs in the management of ischemic heart disease. Am J Cardiovasc Drugs. 2001;1: 23-35.
9. MacInnes A, Fairman DA, Binding P, et al. The antianginal agent trimetazidine does not exert its functional benefit via inhibition of mitochondrial long-chain 3-ketoacyl coenzyme a thiolase. Circ Res. 2003;93: e26-e32.
10. Lopaschuk GD, Barr R, Thomas PD, et al. Beneficial effects of trimetazidine in ex vivo working ischemic hearts are due to a stimulation of glucose oxidation secondary to inhibition of long-chain 3-ketoacyl co-enzyme a thiolase. Circ Res. 2003;93:e33-e37.
11. Elimadi A, Settaf A, Morini D, et al. Trimetazidine counteracts the hepatic injury associated with ischemia-reperfusion by preserving mitochondrial function. J Pharmacol Exp Ther. 1998;286:23-28.
12. Hauet T, Goujon JM, Vandewalle A, et al. Trimetazidine reduces renal dysfunction by limiting the cold ischemia/reperfusion injury in autotransplanted pig kidneys. J Am Soc Nephrol. 2000;11:138-148.
13. Settaf A, Morin D, Lamchouri F, et al. Trimetazidine ameliorates the hepatic injury associated with ischemia-reperfusion in rats. Pharmacol Res. 1999;39:211-216.
14. Lewandowski ED. Metabolic mechanisms associated with antianginal therapy. Circ Res. 2000;86:487-489.
15. Entman ML, Smith CW. Postreperfusion inflammation: a model for reaction to injury in cardiovascular disease. Cardiovasc Res. 1994;28: 1301-1311.
16. Ambrosio G, Tritto I. Reperfusion injury: experimental evidence and clinical implications. Am Heart J. 1999;138:S69-S75.
17. Bolli R, Patel BS, Jeroudi MO, et al. Demonstration of free radical generation in "stunned" myocardium of intact dogs with the use of the spin trap alpha-phenyl N-tert-butyl nitron. J Clin Invest. 1988;82:476-485.
18. Zweier JL. Measurement of superoxide-derived free radicals in the reperfused heart. J Biol Chem. 1988;263:1353-1357.
19. Engler RL, Schmid-Schonbein GW, Pavalel RS, et al. Leukocyte capillary plugging in myocardial ischemia and reperfusion in the dog. Am J Pathol. 1983;111:2407-2412.
20. Ambrosio G, Weisman HF, Mannisi JA, et al. Progressive impairment of regional myocardial perfusion after initial restoration of postischemic blood flow. Circulation. 1989;80:1846-1861.
21. Granger DN, Benoit JN, Suzuki M, et al. Leukocyte adherence to venular endothelium during ischemia-reperfusion. Am J Physiol. 1989;257:G683-G688.
22. 2 radicals during reperfusion after prolonged myocardial ischemia. Am J Physiol Heart Circ Physiol. 2001;280:H2649-H2655.
23. Ambrosio G, Becker LC, Hutchins GM, et al. Reduction in experimental infarct size by recombinant human Superoxide dismutase: insights into the pathophysiology of reperfusion injury. Circulation. 1986;74:1424-1433.
24. Babbitt DG, Virmani R, Forman MB. Intracoronary adenosine administered after reperfusion limits vascular injury after prolonged ischemia in the canine model. Circulation. 1989;80:1388-1399.
25. Bajaj AK, Cobb MA, Virmani R, et al. Limitation of myocardial reperfusion injury by intravenous perfluorochemicals. Role of neutrophil activation. Circulation. 1989;79:645-656.
26. Bolli R, Jeroudi MO, Patel BS, et al. Marked reduction of free radical generation and contractile dysfunction by antioxidant therapy begun at the time of reperfusion. Evidence that myocardial "stunning" is a manifestation of reperfusion injury. Circ Res. 1989;65:607-622.
27. Litt MR, Jeremy RW, Weisman HF, et al. Neutrophil depletion limited to reperfusion reduces myocardial infarct size after 90 minutes of ischemia. Evidence for neutrophil-mediated reperfusion injury. Circulation. 1989; 80:1816-1827.
28. Simpson PJ, Todd RF, Mickelson JK, et al. Sustained limitation of myocardial reperfusion injury by a monoclonal antibody that alters leukocyte function. Circulation. 1990;81:226-237.
29. Williams FM, Tanda K, Kus M, et al. Trimetazidine inhibits neutrophil accumulation after myocardial ischemia and reperfusion in rabbits. J Cardiovasc Pharmacol. 1993;22:828-833.
30. Lefer DJ, Shandelya SML, Serrano CV Jr, et al. Cardioprotective actions of a monoclonal antibody against CD-18 in myocardial ischemia-reperfusion injury. Circulation. 1993;88:1779-1787.
31. Shandelya SML, Kuppusamy P, Weisfeldt ML, et al. Evaluation of the role of polymorphonuclear leukocytes on contractile function in myocardial reperfusion injury. Evidence for plasma-mediated leukocyte activation. Circulation. 1996;87:536-546.
32. Shandelya SML, Kuppusamy P, Herskovitz A, et al. Soluble complement receptor type 1 inhibits the complement pathway and prevents contractile failure in the postischemic heart. Evidence that complement activation is required for neutrophil-mediated reperfusion injury. Circulation. 1993;8: 2812-2826.
33. Lefer AM, Campbell B, Shin YK, et al. Simvastatin preserves the ischemic-reperfused myocardium in normocholesterolemic rat hearts. Circulation. 1999;100:178-184.
34. Pabla R, Buda AJ, Flynn DM, et al. Nitric oxide attenuates neutrophil-mediated myocardial contractile dysfunction after ischemia and reperfusion. Circ Res. 1996;78:65-72.
35. Ikeda Y, Young LH, Lefer AM. Attenuation of neutrophil-mediated myocardial ischemia-reperfusion injury by a calpain inhibitor. Am J Physiol Heart Circ Physiol. 2002;282:H1421-H1426.
36. Young LH, Ikeda Y, Scalia R, et al. C-peptide exerts cardioprotective effects in myocardial ischemia-reperfusion. Am J Physiol Heart Circ Physiol. 2000;279:H1453-H1459.
37. Boyum A. Separation of leukocytes from blood and bone marrow. Scand J Clin Lab Invest. 1968;21:77-89.
38. 2+ level and action of phorbol myristate acetate. J Clin Invest. 1987;9:1226-1233.
39. Plaice C. A note on the determination of serum beta-glucuronidase activity. J Clin Chem. 1961;14:661-664.
40. Allen REC, Mead ME, Kelly JL. Phagocyte oxygrnation activity measured by chemiluminescence and chemiluminigenic probing. In: Greenwald RA, ed. CRC Handbook of Methods for Oxygen Radical Research. Boca Raton (FL, USA): CRC Press; 1985:343-351.
41. Betts WH. Detecting oxyradicals by chemiluminescence. In: Greenwald RA, ed. CRC Handbook of Methods for Oxygen Radical Research. Boca Raton (FL, USA): CRC Press; 1985:197-201.
42. McCord J, Fridovich I. The reduction of cytochrome c by milk xanthine oxidase. J Biol Chem. 1968;243:5753-5760.
43. Halliwell B, Gutteridge JMC. Hydroxyl radical assayed by aromatic hydroxylation and deoxyribose degradation. In: Greenwald RA, ed. CRC Handbook of Methods for Oxygen Radical Research. Boca Raton (FL, USA): CRC Press; 1985:177-180.
44. Fraticelli A, Serrano CV Jr, Bochner BS, et al. Hydrogen peroxide and superoxide modulate leukocyte adhesion molecule expression and leukocyte endothelial adhesion. Biochim Biophys Acta. 1996;1310:251-259.
45. Ambrosio G, Zweier JL, Flaherty JT. The relationship between oxygen radical generation and impairment of myocardial energy metabolism following post-ischemic reperfusion. J Mol Cell Cardiol. 1991;23:1359-1374.
46. Maupoil V, Rochette L, Tabard A, et al. Evolution of free radical formation during low-flow ischemia and reperfusion in isolated rat heart. Cardiovasc Drugs Ther. 1990;4:791-796.
47. Charlon y Boucher F, Clauser P, et al. Effect of a 5 day trimetazidine pretreatment in a model of ischemic and reperfused isolated rat heart: spin trapping experiments. Adv Exp Med Biol. 1990;264:377-382.
48. Guarnieri C, Muscari C. Beneficial effects of trimetazidine on mitochondrial function and superoxide production in the cardiac muscle. Cardiovasc Drugs Ther. 1990;4:7814-7815.
49. Kantor PF, Lucien A, Kozak R, et al. The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl Coenzyme A thiolase. Circ Res. 2000;86:580-588.
50. Boucher FR, Hearse DJ, Opie LH. Effects of trimetazidine on ischemic contracture in isolated perfused rat hearts. J Cardiovasc Pharmacol. 1994; 24:45-49.
51. Hugtenburg JG, Jap TJW, Mathy MJ, et al. Cardioprotective effect of trimetazidine and nifedipine in guinea-pig hearts subjected to ischemia. Arch Int Pharmacodyn Ther. 1989;300:186-208.
52. Veitch K, Maisin L, Hue L. Trimetazidine effects on the damage to mitochondrial functions caused by ischemia and reperfusion. Am J Cardiol. 1995;76:25B-30B.
53. Kay L, Finelli C, Aussedat J, et al. Improvement of long term preservation of the isolated arrested rat heart by trimetazidine: effects on the energy state and mitochondrial function. Am J Cardiol. 1995;76:45B-49B.
54. Sentex E, Sergiel JP, Lucien A, et al. Trimetazidine increases phospholipid turnover in ventricular myocytes. Mol Cell Biochem. 1997;175:153-162.